Table 1 Heparin effect on patency after t-PA Heparin Control Bleich
INTRODUCTION
Recombinant tissue plasminogen activator (alteplase, t-PA), administered with intravenous heparin, is the thrombolytic agent most frequently used in the treatment of acute myocardial infarction in the USA. Its estimated market share is 70%. Despite the widespread preference for t-PA, there remain persistent doubts regarding the premises that support its use-in particular, the validity of GUSTO 1 ,2, the study that provides the scientific basis for t-PA's popularity.
THE ORIGINS OF GUSTO
Why was GUSTO undertaken? TIMI-1 had shown t-PA to produce greater earlier coronary patency than streptokinasebut two large trials that compared the drugs head to head, GISSI-2 4 , 5 and ISIS-3 6 , not only failed to disclose a mortality difference but also demonstrated an increased risk of stroke with t-PA. By delivering t-PA in an accelerated fashion, over 1.5 h rather 4h, with about 60mg delivered in 30min instead of 60 min, the GUSTO investigators hoped that even more rapid thrombolysis might ensue. They chose not to give streptokinase in an accelerated fashion7,8, even though White et al. 8 had shown that 1.S million units, delivered over 30 min rather than 60 min, gave better left ventricular function and longer survival, without higher risk of stroke or more hypotension than that observed with t-PA.
The rationale for i. v. heparin in combination with thrombolytics was to reduce the reocclusion rate, the lack of such adjuvants having been suggested as the explanation for t-PA's disappointing performance in the earlier trials. As shown in Table 1 , several studies 9 -11 have indeed shown that administration of heparin with t-PA enhances late coronary patency (Table 1) . However, at 90 min after administration of t-PA, the time at which t-PA was subsequently found to exert a transient patency advantage over streptokinase, Topol and co-workersl/ found no benefit from heparin on coronary patency (Table 1) generally the same throughout the report (a common denominator). In the most recent report from the GUSTO investigators 18 the number of cases given for respective groups is generally the same throughout the article. However, the estimated number of cases from which outcome for each treatment group was derived differed by 45 (SElO) cases for mortality and 100 (18) cases for stroke between the two reportsl-!". Even important information is incomplete. For instance, in more than 25% of the 'nonprotocol-mandated' angiograms there is no information as to the observed patency of coronary arteries 13. (Because early intervention may have contributed to the differences in outcome between treatment groups, perhaps in an adverse way, this information might clarify whether there had in fact been selection bias.)
Reported findings have also been changed after additional scrutiny: enhanced advantages of t-PA were reported when thrombolytic was administered within 4 h of symptoms (a 1. 1 to 1.2% advantage) I; but in data submitted to the Food and Drug Administration this time related advantage was no longer evident, and the overall attributable benefit oft-PA at 30 days, as judged from the new information, could be no more than 0.86%15. Yet, 30-day mortality data given in subsequent publications 14, 18 are identical to those of the original reportI.
The number and timing of rcvascularizations performed in GUSTO may be a pivotal confounder; yet, the numbers of these procedures have not been consistently reported. At the Clinical Research Meeting, 23.1% of the patients were reported to have had in-hospital coronary angioplasty (PTCA) and 9% coronar)' bypass surgery (CABG), with 0.5% more in the t-PA group having received PTCA and 1.2% more CABG. In the New England journal if Medicine reports 1,2 the percentage of patients having undergone PTCA is given as 15%, and yet in Mark et 01. 16 29% of the US patients (6700 of 23 105) were reported as having the procedure-a number that would exceed 15% of the entire cohort (6153 of 41 021). Still in the most recent report l 8 the percentage of US patients said to have had coronary angioplasty is 31% (versus 10% in the non-US cohort), and overall 22% are said to have had this procedure. Notably, in a multivariable analysis of factors affecting 30-day mortality in acute myocardial infarction, based on the GUSTO data, the apparent influence of thrombolytic therapies is included but the effects of coronary bypass surgery and coronary angioplasty are not considered17.
Although patients were randomized to treatment groups, the thrombolytics were identifiable by differences in the manner of their administration I. In addition, treatment group assignment did not necessarily reflect the strategy that was actually followed". Eleven per cent of patients assigned to the subcutaneous heparin group did not receive this drug during the first 24 h in hospital, a deviation that occurred twice as frequently in US patients (14% versus 7%); also, overall 36% of those assigned to the subcutaneous heparin group received intravenous heparin I. Thus, at least 50% of the US cohort assigned to the streptokinase plus subcutaneous heparin group did not receive treatment in this fashion. (In fact, 51% of the US cohort assigned to streptokinase plus subcutaneous heparin received i. v. heparin during their hospital stay in contrast to 15% in the non-US cohort I8. ) The outcome advantages in t-PA-treated patients occurred only in the US cohortl-'. The intra-group survival advantage for t-PA-treated patients in the US was 1.1% better (odds ratio of benefit, 0.834, 95% CI 0.707 to 0.977, P=0.024) than that recorded for those patients in non-US centres. This intra-group difference was not observed for the other treatment groups: 0.3%, streptokinase plus subcutaneous heparin (P=0.594); 0.8%, streptokinase plus i.v, heparin (P=0.132); and -0.5%, combination therapy (P=0.343). Thus, the intra-group survival advantage for t-PA treatment in the US was equal to or greater than its reported inter-group benefits (overall, t-PA versus streptokinase survival advantage)-a finding that would raise doubts about the validity of any study. The GUSTO investigators have begged this criticism, arguing that the lesser (and not statistically significant) difference observed in non-US hospitals does not render the overall findings (determined by the US data) invalid, since statistical testing does not show the differences between the two cohorts to be significantI8, 23 .
Other treatment differences that were present between the US and non-US patients are therefore germane to determining whether the outcome differences were due to confounders. And, indeed, both medical and invasive treatments were used more frequently in the US cohortl''. Not only would the differences in the number of acute interventions performed be important but also their timing. If more early coronary angiograms, with or without 'rescue' PTCA, had been done in patients receiving streptokinase, this difference might have contributed to their worse outcome (early intervention in patients receiving thrombolysis may be detrimentaJ2+·26). It is not unreasonable to suppose that patients receiving streptokinase underwent more early intervention, given their lower early patency", and the overall relatively low patency rate of those patients undergoing angiography not mandated by the study, ranging from 19% for those dying to 52% for those survivingI 3 . Furthermore, even if the acute interventions were not done in a way that might bias the findings, the fact that t-PA produced a survival advantage only in the US cohort suggests that the treatment strategy used in these patients is a necessary condition for observing such outcome differences. That approach entailed in-hospital angiography in 72% of the patients, PTCA in 31% and CABG in 13%, with 53% of the patients undergoing revascularization at least once during the subsequent year l 6 , procedures that resulted in an overall higher complication rate in the US cohortl''. Even if this experience could be applied to the general population, it is not clear whether such a treatment approach would be desirable, especially in view of the low risk profile of the GUSTO population.
The GUSTO investigators have argued that the angiographic findings support the clinical findings 2 . A generic observation of the study is that only complete coronary reperfusion (TIMI-3) is associated with enhanced left ventricular function/ and improved 24 h survival 13. Although the t-PA group had a greater number of TIMI-3 patients at 90 min than did the streptokinase group (54% versus 31%, P<O.001), by 180min the difference was no longer evident (43% versus 38%) and it remained that way at 24h (46% versus 45%) and at 5-7 days (54% versus 58%)2. Moreover, despite the high percentage of TIMI-3 reperfusion in the t-PA treated patients at 90 min and the observation that TIMI-3 90 min patency was overall associated with an improved left ventricular ejection fraction, patients receiving t-PA showed no advantage in left ventricular ejection fraction, either at 90 min or at 5-7 days2. Moreover, the mortality curves comparing outcome differences between streptokinase and t-PA treated patients did not begin to separate until 6-8 h after treatment randomization had begun, which would be 3-5 h after a patency advantage was no longer evidentl i. It is difficult to believe that the outcome differences were due to such a short-lived patency advantage that was not associated with any substantive improvement in left ventricular function.
The accumulated evidence from the coronary thrombolysis clinical trials-? and the findings from experimental reperfusion studies 28,29 indicate that left ventricular function recovery and survival should relate inversely to the delay in beginning treatment. Yet GUSTO, when the data were closely examined, failed to demonstrate a time-related graduated advantage for t-PA 15. Moreover, although 78% of patients were treated in GUSTO within 4 h of onset of symptoms 1 , the median time of arrival for treatment in the US falls outside this window of benefit-", at a time when the trend of the GUSTO data suggests no advantage for t_PA1,15. Although the LATE stud y30 shows additional benefit of t-PA (compared with a group not treated with thrombolytic therapy) with a delay of 7-12h, and ISIS-2 31 shows a similar effect for streptokinase with a delay of 13-24 h, these effects may relate at least in part to nonspecific antithrombotic effects rather than to coronary thrombolysis. In the LATE study, t-PA actions were independent of the administration of heparin, and, in fact, heparin had a greater effect on 24h outcome than t-PA (odds ratio of benefit 0.679, 95% CI 0.565 to 0.817, P=2.9 X 10-5 versus 0.881, 95% CI 0.735 to 1.055, P=0.174) (calculated from Table 7 28). In ISIS-2 31 heparin was not routinely administered, and the beneficial effects of streptokinase may therefore also be related to nonspecific antithrombotic actions of this thrombolytic.
CONCLUSION
With the help of influential advocates and good marketing t-PA has gained pre-eminence in the USA, yet the evidence that buttresses its widespread use is weak. As a clinical trial, GUSTO does not get high marks: it employed randomization but there was a failure to conform with the protocol and an absence of blinding of treatment groups. Record keeping and reporting of data were erratic, confounding interventions abound, and the cohort was skewed, so that the external validity of the study is not clear. When viewed in this context, there is little to suggest that GUSTO has refuted the findings of GISSI-2 and ISIS-3. What is incontrovertable is that t-PA is a more dangerous and much more expensive drug than streptokinase. It should be used only when streptokinase is contraindicated. 
